Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study

The CheckMate274 trial has reported enhanced disease-free survival rates in patients with stage pT3–4/ypT2–4 or pN+ urothelial carcinoma (UC) undergoing adjuvant nivolumab therapy. This study compares prognostic differences between urothelial carcinoma of the bladder (UCB) and upper tract urothelial...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical genitourinary cancer 2024-06, Vol.22 (3), p.102082-102082, Article 102082
Hauptverfasser:	Narita, Chisato, Urabe, Fumihiko, Fukuokaya, Wataru, Iwatani, Kosuke, Imai, Yu, Yasue, Keiji, Mori, Keiichiro, Aikawa, Koichi, Yanagisawa, Takafumi, Kimura, Shoji, Tashiro, Kojiro, Tsuzuki, Shunsuke, Yamada, Yuta, Yuen, Steffi Kar Kei, Teoh, Jeremy Yuen-Chun, Shimomura, Tatsuya, Yamada, Hiroki, Furuta, Akira, Miki, Jun, Kimura, Takahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant immunotherapy candidate CheckMate 274 trial Lymphovascular invasion Upper tract urothelial carcinoma Urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!